Efficacy and Safety of Voclosporin across Patient Subgroups with Proteinuria ≥2 mg/mg : An Integrated Analysis of the AURA-LV and AURORA 1 Studies (EULAR 2023) - Mar 18, 2023 - Abstract #POS0116; Pres time: Jun 1, 2023; 12:25 PM - 12:30 PM; Location: Poster Tour Auditorium 12; "[1]-[4] In a pooled analysis of the Phase 2 AURA-LV and Phase 3 AURORA 1 studies, the addition of voclosporin to mycophenolate mofetil (MMF) and low-dose steroids resulted in earlier and greater reductions in proteinuria across biopsy classes, races, and ethnicities. Conclusion Consistent with results from the overall pooled study population, patients with UPCR ≥2 mg/mg at baseline treated with voclosporin achieved significantly higher renal response rates than patients treated with MMF and low-dose steroids alone regardless of baseline demographics or clinical characteristics. This is clinically relevant given the lack of safe and effective therapies for patients with high proteinuria."
Clinical • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease
|
|
E. Littlejohn 1; S. Almaani2; V. Birardi3; E. Yap3; C. Collins3
|